• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    BioCryst Pharmaceuticals (BCRX) Wins FDA Nod As ORLADEYO Bulls Ask If The Stock Is A Bargain

    Simply Wall St·10/28/2026 08:23:10
    Listen to the news

    BioCryst Pharmaceuticals (BCRX) just secured FDA approval for an oral pellet formulation of ORLADEYO for hereditary angioedema prophylaxis in adults and adolescents, providing a second oral option alongside the existing capsule.

    Against that backdrop, BioCryst Pharmaceuticals’ share price has moved to US$8.10, with a 1-day share price return of 2.79% and a 7-day share price return of 2.02%. Over the last 30 and 90 days, share price returns declined 5.70% and 15.01% respectively. This suggests that enthusiasm around developments such as the ORLADEYO pellet approval is emerging from a weaker near-term trend and sits alongside a year-to-date share price return of 8%, a 1-year total shareholder return of 11.88%, a 3-year total shareholder return of 47.54% and a 5-year total shareholder return that declined 46.50%.

    Scan other rare disease players with oral therapies and see how BioCryst Pharmaceuticals compares against 21 high quality undiscovered gems in this corner of the market.

    Bulls argue that BioCryst Pharmaceuticals’ HAE franchise and new pellet option justify the recent rebound. Bears point to ongoing losses and a weak 90 day move. Which case does the current valuation lean toward?

    Most Popular Narrative: 62% Undervalued

    The most followed valuation storyline pegs BioCryst Pharmaceuticals at a fair value of $21.30, well above the recent $8.10 close, and ties that gap to how investors weigh its HAE franchise, pipeline, and funding profile.

    Strong and sustainable revenue growth for ORLADEYO, supported by increasing new patient prescriptions, expanding prescriber base, and robust retention rates, positions BioCryst to capitalize on the rising prevalence and earlier diagnosis of rare diseases, likely driving sustained top-line expansion and improved profit margins.

    Anticipated approval and launch of new indications such as ORLADEYO granules for pediatric patients and expanded use in HAE with normal C1 inhibitor broadens the addressable market in an environment of growing global healthcare spending on rare disease therapies, which should further increase long-term revenues and earnings visibility.

    See why 29 investors see BioCryst Pharmaceuticals as 62% undervalued.

    The narrative uses a discount rate of 7.8% and arrives at a fair value of $21.30, which implies a 62% discount relative to that estimate based on the current share price. Analysts behind this view are building in revenue of $930.10 million and earnings of $131.30 million by around 2029, along with a future P/E of 63.3x on those earnings assumptions.

    Those same projections rest on a shift from a current net loss of $384.67 million to positive profitability over the next few years, as well as forecast annual earnings growth of 60.42% and a move to an estimated 14.1% profit margin. The model also factors in ongoing share issuance, with analyst expectations that the share count will rise by 7% per year over the next three years, which can affect how much of that future profit flows to each existing shareholder.

    On top of the narrative fair value, Simply Wall St's DCF output suggests BioCryst Pharmaceuticals is trading 90.7% below an estimated future cash flow value of $87.18, again using the current $8.10 price as the reference point. That DCF fair value is based on projected cash flows discounted back at the same 7.8% rate, which means small changes in long range growth or margin expectations can shift the model quite noticeably.

    Both approaches lean heavily on ORLADEYO remaining the primary economic engine while pipeline assets such as navenibart and BCX17725 contribute over time. As a result, concentration risk and competitive pressure in hereditary angioedema feature prominently in the risk section of the narrative. Readers weighing these scenarios may want to stress test their own assumptions around revenue growth of 6.9% per year, the move to positive earnings within three years, and whether a 63.3x future P/E feels realistic for a biotech that is currently unprofitable with negative shareholders' equity.

    Result: Fair Value of $21.30 (UNDERVALUED)

    Still, the narrative hinges on ORLADEYO concentration risk and early stage pipeline bets, where clinical or competitive setbacks could quickly challenge those upside assumptions.

    Find out about the key risks to this BioCryst Pharmaceuticals narrative.

    Next Steps

    Opinion is clearly split on BioCryst Pharmaceuticals, and the only way to cut through the noise is to test the data yourself and move quickly while the market is still recalibrating around this latest approval and valuation work. To see both sides laid out in one place, start by weighing the 3 key rewards and 2 important warning signs.

    Looking for more investment ideas beyond BioCryst Pharmaceuticals?

    If BioCryst Pharmaceuticals has you thinking more broadly about opportunity and risk, this is the moment to widen your scope and pressure test fresh ideas.